PortalPublikationenPassive pre-exposure immunization by tixagevimab/cilgavimab ...

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Standard

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. / Marchesi, Francesco; Salmanton-García, Jon; Buquicchio, Caterina; Itri, Federico; Besson, Caroline; Dávila-Valls, Julio; Martín-Pérez, Sonia; Fianchi, Luana; Rahimli, Laman; Tarantini, Giuseppe; Grifoni, Federica Irene; Sciume, Mariarita; Labrador, Jorge; Cordoba, Raul; López-García, Alberto; Fracchiolla, Nicola S; Farina, Francesca; Ammatuna, Emanuele; Cingolani, Antonella; García-Bordallo, Daniel; Gräfe, Stefanie K; Bilgin, Yavuz M; Dargenio, Michelina; González-López, Tomás José; Guidetti, Anna; Lahmer, Tobias; Lavilla-Rubira, Esperanza; Méndez, Gustavo-Adolfo; Prezioso, Lucia; Schönlein, Martin; Van Doesum, Jaap; Wolf, Dominik; Hersby, Ditte Stampe; Magyari, Ferenc; Van Praet, Jens; Petzer, Verena; Tascini, Carlo; Falces-Romero, Iker; Glenthøj, Andreas; Cornely, Oliver A; Pagano, Livio.

in: J HEMATOL ONCOL, Jahrgang 16, Nr. 1, 01.04.2023, S. 32.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Letter › Forschung › Begutachtung

Harvard

Marchesi, F, Salmanton-García, J, Buquicchio, C, Itri, F, Besson, C, Dávila-Valls, J, Martín-Pérez, S, Fianchi, L, Rahimli, L, Tarantini, G, Grifoni, FI, Sciume, M, Labrador, J, Cordoba, R, López-García, A, Fracchiolla, NS, Farina, F, Ammatuna, E, Cingolani, A, García-Bordallo, D, Gräfe, SK, Bilgin, YM, Dargenio, M, González-López, TJ, Guidetti, A, Lahmer, T, Lavilla-Rubira, E, Méndez, G-A, Prezioso, L, Schönlein, M, Van Doesum, J, Wolf, D, Hersby, DS, Magyari, F, Van Praet, J, Petzer, V, Tascini, C, Falces-Romero, I, Glenthøj, A, Cornely, OA & Pagano, L 2023, 'Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry', J HEMATOL ONCOL, Jg. 16, Nr. 1, S. 32. https://doi.org/10.1186/s13045-023-01423-7

APA

Marchesi, F., Salmanton-García, J., Buquicchio, C., Itri, F., Besson, C., Dávila-Valls, J., Martín-Pérez, S., Fianchi, L., Rahimli, L., Tarantini, G., Grifoni, F. I., Sciume, M., Labrador, J., Cordoba, R., López-García, A., Fracchiolla, N. S., Farina, F., Ammatuna, E., Cingolani, A., ... Pagano, L. (2023). Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J HEMATOL ONCOL, 16(1), 32. https://doi.org/10.1186/s13045-023-01423-7

Vancouver

Marchesi F, Salmanton-García J, Buquicchio C, Itri F, Besson C, Dávila-Valls J et al. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J HEMATOL ONCOL. 2023 Apr 1;16(1):32. https://doi.org/10.1186/s13045-023-01423-7

Bibtex

@article{d8a5f4e378654483b303accf9c857569,
title = "Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry",
abstract = "Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.",
keywords = "Humans, COVID-19/prevention & control, SARS-CoV-2, Hematologic Neoplasms/complications, Antibodies, Monoclonal, Immunization, Passive, Registries",
author = "Francesco Marchesi and Jon Salmanton-Garc{\'i}a and Caterina Buquicchio and Federico Itri and Caroline Besson and Julio D{\'a}vila-Valls and Sonia Mart{\'i}n-P{\'e}rez and Luana Fianchi and Laman Rahimli and Giuseppe Tarantini and Grifoni, {Federica Irene} and Mariarita Sciume and Jorge Labrador and Raul Cordoba and Alberto L{\'o}pez-Garc{\'i}a and Fracchiolla, {Nicola S} and Francesca Farina and Emanuele Ammatuna and Antonella Cingolani and Daniel Garc{\'i}a-Bordallo and Gr{\"a}fe, {Stefanie K} and Bilgin, {Yavuz M} and Michelina Dargenio and Gonz{\'a}lez-L{\'o}pez, {Tom{\'a}s Jos{\'e}} and Anna Guidetti and Tobias Lahmer and Esperanza Lavilla-Rubira and Gustavo-Adolfo M{\'e}ndez and Lucia Prezioso and Martin Sch{\"o}nlein and {Van Doesum}, Jaap and Dominik Wolf and Hersby, {Ditte Stampe} and Ferenc Magyari and {Van Praet}, Jens and Verena Petzer and Carlo Tascini and Iker Falces-Romero and Andreas Glenth{\o}j and Cornely, {Oliver A} and Livio Pagano",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = apr,
day = "1",
doi = "10.1186/s13045-023-01423-7",
language = "English",
volume = "16",
pages = "32",
journal = "J HEMATOL ONCOL",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

AU - Marchesi, Francesco

AU - Salmanton-García, Jon

AU - Buquicchio, Caterina

AU - Itri, Federico

AU - Besson, Caroline

AU - Dávila-Valls, Julio

AU - Martín-Pérez, Sonia

AU - Fianchi, Luana

AU - Rahimli, Laman

AU - Tarantini, Giuseppe

AU - Grifoni, Federica Irene

AU - Sciume, Mariarita

AU - Labrador, Jorge

AU - Cordoba, Raul

AU - López-García, Alberto

AU - Fracchiolla, Nicola S

AU - Farina, Francesca

AU - Ammatuna, Emanuele

AU - Cingolani, Antonella

AU - García-Bordallo, Daniel

AU - Gräfe, Stefanie K

AU - Bilgin, Yavuz M

AU - Dargenio, Michelina

AU - González-López, Tomás José

AU - Guidetti, Anna

AU - Lahmer, Tobias

AU - Lavilla-Rubira, Esperanza

AU - Méndez, Gustavo-Adolfo

AU - Prezioso, Lucia

AU - Schönlein, Martin

AU - Van Doesum, Jaap

AU - Wolf, Dominik

AU - Hersby, Ditte Stampe

AU - Magyari, Ferenc

AU - Van Praet, Jens

AU - Petzer, Verena

AU - Tascini, Carlo

AU - Falces-Romero, Iker

AU - Glenthøj, Andreas

AU - Cornely, Oliver A

AU - Pagano, Livio

N1 - © 2023. The Author(s).

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

AB - Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

KW - Humans

KW - COVID-19/prevention & control

KW - SARS-CoV-2

KW - Hematologic Neoplasms/complications

KW - Antibodies, Monoclonal

KW - Immunization, Passive

KW - Registries

U2 - 10.1186/s13045-023-01423-7

DO - 10.1186/s13045-023-01423-7

M3 - Letter

C2 - 37005697

VL - 16

SP - 32

JO - J HEMATOL ONCOL

JF - J HEMATOL ONCOL

SN - 1756-8722

IS - 1

ER -